drugset / Trial / NCT04264676

Summary

Fusobacterium nucleatum (Fusobacterium nucleatum, Fn) has been identified as an independent risk factor for recurrence of colorectal cancer. In this study, oral metronidazole would be used to reduce the abundance of Fn in patients with high Fn, so as to explore whether oral metronidazole can improve the efficacy of postoperative chemotherapy in patients with colorectal cancer.

Timeline

Start
2020-03-31
Primary completion
2023-03
Completion
2025-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metronidazole Small molecule 0.4 g Oral

Indications